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Background. The role of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in
sepsis after major abdominal surgery and sepsis-associated organ dysfunction is unexplored. Materials and Methods. Fifty-three
patients with sepsis after major abdominal surgery were compared to 50 operated and 50 nonoperated controls. MMP-9, TIMP-1,
biomarkers of inﬂammation, kidney and liver injury, coagulation, and metabolic disorders were measured daily during 96 h
following diagnosis of sepsis and once in controls. MMP-9/TIMP-1 ratios and disease severity scores were calculated. Use of
vasopressors/inotropes, mechanical ventilation, and survival were recorded. Results. Septic patients had lower MMP-9 and
MMP-9/TIMP-1 ratios but higher TIMP-1 levels compared to controls. AUC-ROC for diagnosis of sepsis was 0.940 and 0.854
for TIMP-1 and 0.924 and 0.788 for MMP-9/TIMP-1 ratio (sepsis versus nonoperated and sepsis versus operated controls, resp.).
Lower MMP-9 and MMP-9/TIMP-1 ratio and higher TIMP-1 levels were associated with shorter survival. MMP-9, TIMP-1,
and MMP-9/TIMP-1 ratio correlated with biomarkers of inﬂammation, kidney and liver injury, coagulation, metabolic
disorders, and disease severity scores. Use of vasopressors/inotropes was associated with higher TIMP-1 levels. Conclusions.
MMP-9, TIMP-1, and MMP-9/TIMP ratio were good diagnostic or prognostic biomarkers of sepsis after major abdominal
surgery and were linked to sepsis-associated organ dysfunction.
1. Introduction
Sepsis, a systemic inﬂammation caused by infection, is cur-
rently the leading cause of death in surgical intensive care
units (SICUs) [1] with a mortality rate approaching 65%
[2]. An overwhelming inﬂammatory response, the hallmark
of this condition, could lead to the dysfunction of virtually
every major organ or tissue [3].
Matrix metalloproteinase-9 (MMP-9), a zinc-dependent
proteinase, is released by various inﬂammatory cells, predom-
inantly neutrophils and macrophages. Together with its
endogenous inhibitor, tissue inhibitor of metalloproteinase-1
(TIMP-1), it regulates numerous signaling pathways of pivotal
importance in inﬂammation [4–6].
The association of MMP-9 and TIMP-1 with severity and
outcome of sepsis has already been recognised [7–15]. How-
ever, these biomarkers were not explored in surgical sepsis
which is considered signiﬁcantly diﬀerent from sepsis in
medical patients [16] or in major abdominal surgery per se.
Also, aside from acute kidney injury (AKI) [17], the associa-
tion of MMP-9 and TIMP-1 with the clinical manifestations
of sepsis-associated organ dysfunction has not yet been
investigated despite numerous animal models of sepsis that
clearly demonstrate elevated expression of these biomarkers
in the kidney [18], lung [18–21], liver [18, 21], brain [22],
heart [23], and endothelium [24].
The objectives of this study were to investigate, for
the ﬁrst time, MMP-9, TIMP-1, and the MMP-9/TIMP-1
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ratio as diagnostic and prognostic biomarkers of sepsis
after major abdominal surgery as well as the potential rela-
tionships between these biomarkers and sepsis-associated
organ dysfunction.
2. Materials and Methods
2.1. Design and Patients. This prospective, observational
study included 153 consecutive consenting adult patients
admitted to the University Hospital Department of Surgery
and SICU. The study has been approved by the institution’s
Ethics Committee. Written consents were obtained from
patients or their legal representatives.
Patients were allocated to three study groups: sepsis
group (n = 53), operated controls (n = 50), and nonoperated
controls (n = 50). Inclusion criteria for the sepsis group were
admission to SICU for the treatment of sepsis, sepsis pre-
sumed to be abdominal in origin, and at least one major
abdominal surgical procedure performed during the current
hospitalization. Inclusion criteria for the operated control
group were American Society of Anesthesiologists (ASA)
physical status 2, routine admission to SICU after major
abdominal surgery, and uneventful recovery. Inclusion cri-
teria for the nonoperated control group were ASA physical
status 2, admission to the Department of Surgery prior to
the major abdominal surgery, and no signs of inﬂammation
or infection at the time of blood sampling. Major abdominal
surgery was deﬁned as a surgical procedure in which the
peritoneum is entered, organs are removed, or normal
anatomy is altered. Exclusion criteria were age< 18 years,
sepsis of fungal or viral origin, sepsis of extra abdominal ori-
gin, chemotherapy and radiotherapy in the past 30 days,
immunosuppressant therapy, major trauma, burns, end-
stage organ disease, cardiogenic or hemorrhagic shock, and
participation in another clinical trial during this hospitaliza-
tion. All patients received routine treatment and care.
2.2. Clinical Assessment. Demographic (age, gender) and
clinical (comorbidities, type of surgery, use of vasopressors/
inotropes, use of mechanical ventilation, and 28-day sur-
vival) data were obtained from medical records. Sepsis was
diagnosed according to the Surviving Sepsis Campaign cri-
teria [25]. Assessment of comorbidities was performed in
all patients using ASA physical status [26]. In septic patients,
only comorbidities present prior to sepsis were considered
and all the changes in physical status subsequently caused
by sepsis were disregarded. In both control groups, ASA
physical status was assessed prior to surgery. Disease severity
scores, Acute Physiology and Chronic Health Evaluation II
(APACHE II) score [27] and Sequential Organ Failure
Assessment (SOFA) score [28], were calculated daily at the
time of sample collection.
Sepsis-associated organ dysfunction was assessed using
the following biomarker groups: inﬂammation—white
blood cell (WBC) count, C-reactive protein (CRP), and
procalcitonin (PCT); kidney injury—serum urea, creatinine,
serum and urine neutrophil gelatinase-associated lipocalin
(NGAL), and urine kidney injury molecule-1 (KIM-1);
liver injury—aspartate aminotransferase (AST), alanine
aminotransferase (ALT), and total and direct bilirubin;
coagulation—platelet count, international normalized ratio
(INR), and activated partial thromboplastin time (aPTT);
and metabolic disorders—serum protein, glucose, and lac-
tate. Use of vasopressors/inotropes was suggestive of car-
diovascular dysfunction. Use of mechanical ventilation
implied lung injury.
2.3. Blood and Urine Sample Collection. Blood and urine sam-
ples from the septic patients were collected during the ﬁrst
hour following admission to SICU (0 hour) and thereafter
at 24, 48, 72, and 96 hours. Samples from the operated con-
trols were collected once during the routine postoperative
SICU stay and once from the nonoperated controls after fast-
ing for the night.
2.4. MMP-9 and TIMP-1 Measurement and MMP-9/TIMP-1
Ratio Calculation. Blood was drawn into standard collec-
tion tubes with a cloth activator. Urine samples were col-
lected using a standard catheter stream urine collection
technique. Centrifuged serum and urine aliquots were then
stored to −80°C until further analysis which was per-
formed in batches. MMP-9 and TIMP-1 levels were mea-
sured using enzyme-linked immunosorbent assays (ELISA)
(R&D Systems, MN, USA). Intra-assay precision (CV%)
was 2.9% and 4.2% for MMP-9 and TIMP-1, respectively.
Interassay precision (CV%) was 6.9% and 4.9% for MMP-9
and TIMP-1, respectively. The MMP-9/TIMP-1 ratio was
calculated as follows: MMP-9/TIMP-1 ratio =MMP-9
(ng/mL)/TIMP-1 (ng/mL).
2.5. Other Laboratory Parameters. Blood samples were proc-
essed immediately after collection. CRP and PCT levels were
measured using immunoturbidimetric and enzyme-linked
ﬂuorescent assays, respectively (bioMérieux, Lion, France).
Serum and urine NGAL and urine KIM-1 levels were
determined employing the ELISA technique (Abbott Diag-
nostics, IL, USA, and R&D Systems Inc., MN, USA, resp.).
Serum urea, creatinine, AST, ALT, total and direct biliru-
bin, INR, aPTT, total protein, and glucose levels were
measured using routine laboratory methods (Roche Diagnos-
tics reagents using Roche Cobas c501, Mannheim, Germany).
WBC count and platelet count were measured employing
an automated hematology analyzer (ABX Horiba, Pentra
DX 120, Montpellier, France). Lactate levels were mea-
sured using an automated blood gas analyzer (GEM Pre-
mier 3000, Instrumentation Laboratory, Milan, Italy).
2.6. Statistical Analysis. Statistical analysis was performed in
SPSS Version 25 software (SPSS Inc., Chicago, IL, USA).
Normality of the data distribution was evaluated by the
Kolmogorov-Smirnov test. Categorical variables were
reported as frequencies and continuous variables as medians
and interquartile ranges. The Mann–Whitney U or chi-
square test was used for comparisons between two inde-
pendent samples and Friedman’s repeated measures test
for comparison between related samples. The diagnostic
power of the tested biomarkers was evaluated by calculat-
ing the areas under receiver operating characteristic curves
(AUC-ROC). Kaplan-Meier estimates of 28-day survival
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with the log-rank test were also performed. Correlations
were analyzed employing the Kendall tau-b test. Both
correlation and Kaplan-Meier analysis were performed
using baseline values of the tested biomarkers as indepen-
dent variables. The diﬀerence between the groups of sep-
tic patients over time was assessed using linear mixed
models with compound symmetry as the repeated covari-
ance type. The minimal statistical signiﬁcance was set at
two-tailed p < 0 05.
3. Results
3.1. Comparison between Patients with Sepsis and Control
Groups. Baseline characteristics of the three patient groups
are displayed in Table 1. Patient groups were similar in age,
gender, and comorbidities represented by ASA scores. Septic
patients and operated controls were similar in terms of the
type of surgery. Patients with sepsis had higher disease sever-
ity scores compared to both control groups as did operated
Table 1: Baseline demographic, clinical, and laboratory characteristics.
Nonoperated controls (N = 50) Operated controls (N = 50) Sepsis (N = 53)
Demographic and clinical characteristics
Age (years) 60.00 (54.75–72.00) 65.00 (57.75–74.00) 70.00 (60.00–75.50)
Gender (m/f) 23/27 22/28 28/25
ASA (1/2/3/4/5) 0/50/0/0/0 0/50/0/0/0 2/47/4/0/0
Surgery (upper gastrointestinal/colorectal) NA 9/41 18/35
Disease severity scores
APACHE II 4.00 (2.00–5.25) 7.00 (5.00–7.50)a 21.50 (16.00–28.00)b,c
SOFA 0 (0–0) 0 (0–0) 7 (4–10)b,c
Biomarkers of inﬂammation
MMP-9 (ng/mL) 895.6 (665.5–1157.9) 663.3 (537.2–726.1)a 572.9 (391.5–997.8)b
TIMP-1 (ng/mL) 219.9 (170.6–292.4) 263.0 (153.2–428.0) 558.7 (469.9–875.8)b,c
MMP-9/TIMP-1 ratio 3.88 (3.26–5.93) 2.47 (1.59–3.61)a 0.94 (0.50–2.27)b,c
WBC count× 109/L 7.0 (5.5–8.2) 9.1 (6.5–12.1)a 13.8 (9.0–18.6)b,c
CRP (mg/L) — 97.5 (14.8–157.2) 197.8 (148.3–256.1)c
PCT (μg/L) — — 12.96 (3.17–30.47)
Biomarkers of kidney injury
Urea (mmol/L) 4.8 (3.7–5.7) 4.9 (3.6–6.7) 12.9 (8.2–19.7)b,c
Creatinine (μmol/L) 79.0 (65.0–85.0) 74.0 (56.8–92.0) 133.3 (93.5–203.2)b,c
Serum NGAL (ng/mL) 87.3 (82.2–95.3) 100.3 (91.2–111.9)a 169.0 (105.5–200.9)b,c
Urine NGAL (ng/mL) 14.6 (7.8–68.9) 42.9 (27.2–57.6)a 107.1 (46.7–204.5)b,c
Urine KIM-1 (pg/mL) 740.5 (233.5–919.3) 800.0 (730.0–1977.0)a 790.0 (712.0–1309.7)b
Biomarkers of liver injury
AST (IU/L) 19 (16–25) 29 (19–111)a 47 (28–118)b
ALT (IU/L) 21 (14–34) 31 (19–99) 35 (18–78)b
Total bilirubin (μmol/L) 9.1 (5.9–18.8) 17.3 (10.1–36.2)a 16.8 (11.8–46.1)b
Direct bilirubin (μmol/L) 3.30 (2.05–8.55) 8.85 (5.97–20.05)a 6.75 (5.40–26.42)b
Biomarkers of coagulation
Platelets× 109/L 254 (199–291) 198 (177–265)a 223 (142–316)
INR 1.21 (1.03–1.38) 1.19 (1.05–1.32) 1.41 (1.13–1.96)b,c
aPTT (s) 35 (28–41) 36 (27–43) 46 (37–59)b,c
Biomarkers of metabolic disorders
Protein (g/L) 66.9 (61.8–73.0) 56.5 (45.8–62.2)a 35.1 (28.5–45.9)b,c
Glucose (mmol/L) 5.6 (5.0–6.1) 6.4 (5.9–8.3)a 8.2 (5.8–11.1)b,c
Lactate (mmol/L) — — 1.30 (1.00–3.90)
Data are presented as median and 25th–75th percentile values or frequencies. aSigniﬁcant diﬀerence between operated and nonoperated controls, bsigniﬁcant
diﬀerence between the sepsis group and nonoperated controls, and csigniﬁcant diﬀerence between the sepsis group and operated controls. Mann–WhitneyU or
chi-square test; p < 0 05 is considered statistically signiﬁcant. ASA: American Society of Anesthesiologists physical status; APACHE II: Acute Physiology and
Chronic Health Evaluation II score; SOFA: Sequential Organ Failure Assessment score; MMP-9: matrix metalloproteinase-9; TIMP-1: tissue inhibitor of matrix
metalloproteinase-1; WBC: white blood cell; CRP: C-reactive protein; PCT: procalcitonin; NGAL: neutrophil gelatinase-associated lipocalin; KIM-1: kidney
injury molecule-1; AST: aspartate aminotransferase; ALT: alanine aminotransferase; INR: international normalized ratio; aPTT: activated partial
thromboplastin time.
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Figure 1: Dynamics of (a) MMP-9, (b) TIMP-1, and (c) MMP-9/TIMP-1 ratio in patients with sepsis in comparison to control groups. Data
are expressed as minimum, maximum, median, and interquartile range. Blue—nonoperated controls, green—operated controls, and
red—sepsis. ∗Statistically signiﬁcant diﬀerence compared to nonoperated controls. #Statistically signiﬁcant diﬀerence compared to
operated controls. Mann–Whitney U test; p < 0 05 is considered statistically signiﬁcant. MMP-9: matrix metalloproteinase-9; TIMP-1:
tissue inhibitor of matrix metalloproteinase-1.
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controls compared to nonoperated controls. On admission to
SICU, septic patients had, compared to controls, lower
MMP-9, MMP-9/TIMP-1 ratio, and protein levels but higher
TIMP-1, WBC, CRP, urea, creatinine, NGAL, KIM-1, INR,
aPTT, and blood glucose.
Figure 1 depicts the dynamics of MMP-9, TIMP-1, and
MMP-9/TIMP-1 ratio in patients with sepsis compared to
both control groups. Levels of these biomarkers did not
change signiﬁcantly during 96 h following admission to SICU
(p > 0 05 for all the three parameters). Patients with sepsis
had lower levels of MMP-9 on admission to SICU and 24 h
later than nonoperated controls, but such levels of MMP-9
were similar to those in operated controls (Figure 1(a)).
Patients with sepsis had higher TIMP-1 levels (Figure 1(b))
and lower MMP-9/TIMP-1 ratios (Figure 1(c)) than both
control groups at all time points. Operated controls also
had lower MMP-9/TIMP-1 ratio relative to nonoperated
controls (Figure 1(c)).
3.2. MMP-9, TIMP-1, and MMP-9/TIMP-1 Ratio as
Diagnostic Biomarkers of Sepsis. The evaluation of MMP-9,
TIMP-1, andMMP-9/TIMP-1 ratio as diagnostic biomarkers
of sepsis was performed by the calculation of AUC-ROC
values (Table 2). TIMP-1 and MMP-9/TIMP ratio were,
unlike MMP-9, very good discriminators between patients
with sepsis and both control groups at all time points. Also,
MMP-9 and MMP-9/TIMP-1 ratio discriminated operated
from nonoperated controls.
3.3. MMP-9, TIMP-1, and MMP-9/TIMP-1 Ratio as
Prognostic Biomarkers of Sepsis. Twenty-eight septic patients
(52.8%) died during the SICU stay. Lower MMP-9
(Figure 2(a)) and MMP-9/TIMP-1 ratio (Figure 2(c)) as well
higher TIMP-1 (Figure 2(b)) were associated with shorter
28-day survival.
3.4. The Relationship between MMP-9, TIMP-1, and MMP-9/
TIMP-1 Ratio and Sepsis-Associated Organ Dysfunction. Not
surprisingly, MMP-9 and MMP-9/TIMP-1 ratio correlated
directly with WBC count but indirectly with PCT levels.
Lower MMP-9 and MMP-9/TIMP-1 ratio and higher
TIMP-1 levels were associated with kidney and liver injury,
coagulopathy, elevated lactate and glucose levels, and
lower protein levels. MMP-9 and MMP-9/TIMP-1 ratio
correlated negatively and TIMP-1 positively with disease
severity scores (Table 3).
Twenty-three (43.4%) septic patients were treated with
vasopressors/inotropes, and 41 (77.4%) received mechanical
ventilation. During 96 h following admission to SICU,
TIMP-1 values were, unlike those of MMP-9 and MMP-9/
TIMP-1 ratio, signiﬁcantly higher in the septic patients
treated with vasopressors/inotropes. Septic patients receiving
mechanical ventilation had similar values of these bio-
markers over time compared to the septic patients who did
not receive mechanical ventilation (Figure 3).
4. Discussion
The principal novelties of this study are (1) the explora-
tion of MMP-9, TIMP-1, and MMP-9/TIMP-1 ratio as
biomarkers of sepsis speciﬁcally after major abdominal
surgery and (2) the investigation of the potential relation-
ships between these biomarkers and the sepsis-associated
organ dysfunction.
4.1. Comparison between Patients with Sepsis and Control
Groups. In our study, MMP-9 levels in septic patients were
similar to those in operated controls but lower than those
in nonoperated controls. According to literature, when septic
patients were compared to healthy controls [10–13], higher
MMP-9 levels were reported, but when compared to
Table 2: MMP-9, TIMP-1, and MMP-9/TIMP-1 ratio as diagnostic biomarkers of sepsis.
AUC-ROC (95% CI)
MMP-9 TIMP-1 MMP-9/TIMP-1 ratio
Nonoperated controls versus operated controls
0 h 0.798 (0.702–0.895)∗ 0.584 (0.465–0.704) 0.761 (0.664–0.858)∗
Sepsis versus nonoperated controls
0 h 0.675 (0.561–0.789)∗ 0.940 (0.889–0.991)∗ 0.924 (0.873–0.975)∗
24 h 0.640 (0.511–0.769)∗ 0.972 (0.941–1.004)∗ 0.929 (0.878–0.980)∗
48 h 0.593 (0.450–0.736) 0.929 (0.862–0.997)∗ 0.914 (0.853–0.975)∗
72 h 0.591 (0.417–0.765) 0.951 (0.892–1.006)∗ 0.901 (0.821–0.980)∗
96 h 0.646 (0.457–0.826) 0.925 (0.825–1.026)∗ 0.911 (0.825–0.997)∗
Sepsis versus operated controls
0 h 0.541 (0.418–0.664) 0.854 (0.778–0.930)∗ 0.788 (0.697–0.879)∗
24 h 0.513 (0.372–0.653) 0.870 (0.797–0.943)∗ 0.753 (0.650–0.855)∗
48 h 0.570 (0.415–0.724) 0.820 (0.728–0.913)∗ 0.718 (0.605–0.832)∗
72 h 0.523 (0.342–0.703) 0.857 (0.768–0.913)∗ 0.724 (0.593–0.854)∗
96 h 0.514 (0.307–0.721) 0.845 (0.738–0.952)∗ 0.750 (0.612–0.888)∗
Data are presented as AUC-ROC (95% CI). ∗p < 0 05. AUC-ROC: area under receiver operating characteristic curve; MMP-9: matrix metalloproteinase-9;
TIMP-1: tissue inhibitor of matrix metalloproteinase-1.
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nonseptic ICU patients [9] or febrile controls [7], lower
MMP-9 levels were found. It becomes clear that the study
design has an important role in the interpretation of these
results especially considering the inﬂuence of comorbidities
[5, 6] and major surgery [27, 28] on MMP-9 levels. The
unique design of our study enabled control over the inﬂuence
of these confounding factors. Our results also suggest that
major abdominal surgery, independent of sepsis, is associated
with lower MMP-9 levels. Additionally, there is evidence of
postoperative MMP-9 storage depletion [29] and lowering
of MMP-9 levels related to ﬂuid administration during major
surgery [30].
As opposed to MMP-9, TIMP-1 levels are repeatedly
reported to be higher in sepsis [7, 8, 10–13]. Not surprisingly,
our patients also had higher TIMP-1 levels and, conse-
quently, lower MMP-9/TIMP-1 ratios compared to both
control groups at all time points.
4.2. MMP-9, TIMP-1, and MMP-9/TIMP-1 Ratio as
Diagnostic Biomarkers of Sepsis. ROC curve analysis showed
that TIMP-1 and MMP-9/TIMP-1 ratio were very good
diagnostic biomarkers of sepsis after major abdominal sur-
gery. Furthermore, AUC-ROC values were similar at all time
points which suggests that their diagnostic value remains
relevant for at least 96 h. This feature could be potentially
very useful if recognition of sepsis is delayed which, unfortu-
nately, is not uncommon in daily clinical practice [25].
AUC-ROC values were quite high and comparable to those
in pediatric sepsis [7] and were even slightly higher than
those of PCT, the established biomarker of sepsis [31, 32].
Our results also showed that MMP-9 was a poor discrimina-
tor between the septic patients and controls. Martin et al.
found that MMP-9 had only moderate capacity to diagnose
sepsis (AUC-ROC 0.73 (0.65–0.80)) [9]. Poor diagnostic per-
formance of MMP-9 is not surprising considering the large
variability of the reported values [7–10, 13].
4.3. MMP-9, TIMP-1, and MMP-9/TIMP-1 Ratio as
Prognostic Biomarkers of Sepsis. Our results suggest that
lower MMP-9 and MMP-9/TIMP-1 ratio but higher TIMP-1
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Figure 2: Kaplan-Meier estimates of 28-day survival based on (a) MMP-9, (b) TIMP-1, and (c) MMP-9/TIMP-1 ratio quartiles. Blue
line—1st quartile, green line—2nd quartile, yellow line—3rd quartile, and red line—4th quartile. Log rank: (a) MMP-9 (p = 0 002),
(b) TIMP-1 (p ≤ 0 001, and (c) MMP-9/TIMP-1 ratio (p < 0 001).
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levels are associated with higher mortality rates and, accord-
ingly, higherdisease severity scores.Previous studies alsodem-
onstrated lower MMP-9 [8, 9, 15] and higher TIMP-1 [8, 12,
13, 15] in nonsurvivors and in patients with higher disease
severity scores [6, 12]. Lorente et al. [8] and Wang et al. [13],
as opposed to Martin et al. [9] and Serrano-Gomez et al. [14],
supported our ﬁndings that MMP-9, TIMP-1, and MMP-9/
TIMP-1 ratio are good prognostic biomarkers of 28-day sur-
vival. A recent study by Niño et al., however, demonstrated
that only TIMP-1 and notMMP-9 andMMP-9/TIMP-1 ratio
was a good predictor of mortality in sepsis [15].
Previously discussed diagnostic and prognostic value of
the proposed biomarkers suggests that they should be
explored in larger patient populations. Considering that
these biomarkers were not used in routine clinical practice,
it is diﬃcult to estimate their economic impact. However,
since the established biomarkers of sepsis, in particular
PCT and CRP, are costly assayed, there is an opportunity
for more aﬀordable ones to gain clinical acceptance. On that
note, given that MMP-9 is inferior in its diagnostic and prog-
nostic performance to TIMP-1, the use of theMMP-9/TIMP-
1 ratio could not be economically justiﬁed.
4.4. The Relation between MMP-9, TIMP-1, and MMP-9/
TIMP-1 Ratio and Sepsis-Associated Organ Dysfunction.
WBC count, CRP, and PCT are widely used in clinical prac-
tice as diagnostic and prognostic biomarkers of inﬂamma-
tion, infection, and sepsis [33, 34]. Our study reports a
positive correlation between WBC count and MMP-9 levels
that was expected considering the origin of MMP-9 [6]. Sim-
ilar to earlier reports [7, 9], MMP-9, TIMP-1, and MMP-9/
TIMP-1 ratio were not signiﬁcantly related to CRP levels.
Wang et al. found a positive correlation between PCT and
TIMP-1 [13] while our results suggest a negative correlation
between PCT and MMP-9. A negative correlation between
PCT and MMP-9 is expected given the association of higher
PCT levels with more severe forms of sepsis [25, 33]. Accord-
ing to our results, lower MMP-9 levels could be found in
patients with higher disease severity scores.
In our study, low MMP-9 and high TIMP-1 levels were
associated with more severe kidney and liver injury. This
was supported by Renckens et al. who demonstrated that
MMP-9-knockout mice with abdominal sepsis developed
more severe distant organ damage [21]. On the other hand,
elevated MMP-9 and TIMP-1 expression was found in kid-
neys and livers of animal models of sepsis [18, 21]. A more
detailed comment on the role of these biomarkers in septic
AKI could be found in our earlier paper [17], but clinical
reports on MMP-9 and TIMP-1 in sepsis-associated liver
injury are lacking.
The association of MMP-9 and TIMP-1 with platelet
count, INR, and aPTT is not surprising given the previous
ﬁndings of Lorente et al. [8] and the more complex
coagulation-independent interaction between platelets and
MMP-9 [35].
According to our results, low MMP-9 and MMP-9/
TIMP-1 ratio but high TIMP-1 values were associated with
lower protein and higher blood glucose and lactate levels
which is consistent with some previous ﬁnding [8, 36].
We found that TIMP-1 values were signiﬁcantly higher
in the septic patients treated with vasopressors/inotropes.
Clinical studies on this topic are lacking, but experimental
models imply that catecholamines have a very complex inter-
action with MMPs and their inhibitors [37, 38] that could be
inﬂuenced by various medications, none of which are
accounted for in this research.
Septic patients receiving mechanical ventilation had sim-
ilar MMP-9 and TIMP-1 values compared to the septic
patients who did not receive mechanical ventilation. Possible
explanation could be found in the interaction of the opposing
Table 3: Correlation analysis.
MMP-9 TIMP-1
MMP-9/
TIMP-1 ratio
Disease severity scores
APACHE II −0.099 0.107 −0.116∗
SOFA −0.149∗∗ 0.181∗∗ −0.196∗∗
Biomarkers of inﬂammation
WBC 0.377∗∗ 0.018 0.268∗∗
CRP −0.047 0.019 −0.037
PCT −0.246∗∗ 0.150 −0.214∗∗
Biomarkers of kidney injury
Urea −0.154∗∗ 0.103 −0.167∗∗
Creatinine −0.187∗∗ 0.153∗∗ −0.234∗∗
Serum NGAL −0.089 0.271∗∗ −0.203∗∗
Urine NGAL −0.277∗∗ 0.197∗∗ −0.338∗∗
KIM-1 0.002 0.144∗∗ −0.104
Biomarkers of liver injury
AST −0.145∗ 0.236∗∗ −0.210∗∗
ALT −0.051 0.148∗ −0.097
Total bilirubin −0.290∗∗ 0.102 −0.266∗∗
Direct bilirubin −0.299∗∗ 0.143 −0.263∗∗
Biomarkers of coagulation
Platelets 0.371∗∗ −0.103 0.329∗∗
INR −0.112 0.153∗ −0.127
aPTT −0.143∗ 0.102∗ 0.135∗
Biomarkers of metabolic
disorders
Total protein 0.113∗ −0.109∗ 0.120∗
Glucose −0.062 0.270∗∗ −0.246∗∗
Lactate −0.211∗∗ 0.263∗∗ −0.275∗∗
Kendall’s Tau-b correlation analysis. ∗∗The correlation is signiﬁcant at the
0.01 level (2-tailed); ∗ the correlation is signiﬁcant at the 0.05 level
(2-tailed). MMP-9: matrix metalloproteinase-9; TIMP-1: tissue inhibitor
of matrix metalloproteinase-1; APACHE II: Acute Physiology and
Chronic Health Evaluation II score; SOFA: Sequential Organ Failure
Assessment score; WBC: white blood cell; CRP: C-reactive protein; PCT:
procalcitonin; NGAL: neutrophil gelatinase-associated lipocalin; KIM-1:
kidney injury molecule-1; AST: aspartate aminotransferase; ALT: alanine
aminotransferase; INR: international normalized ratio; aPTT: activated
partial thromboplastin time.
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factors inﬂuencing the levels of these biomarkers. Sepsis-
associated lung injury is linked to elevated MMP-9 and
TIMP-1 lung expression [18–21], but mechanical ventilation
per se is related to reduction in MMP-9 and TIMP-1 levels
[39]. Also, beta-agonists have a potential to alter MMP-9
and TIMP-1 levels [40]. Additionally, the use of mechanical
ventilation could be prompted by reasons other than lung
injury (hemodynamic instability, increase in intracranial
pressure, etc.).
Our study has several limitations. Firstly, it is possible
that the relatively small number of patients could have added
to the large variability in the data. Secondly, due to the limit
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Figure 3: MMP-9, TIMP-1, and MMP-9/TIMP-1 ratio in septic patients receiving (a, b, c) vasopressors/inotropes or (d, e, f) mechanical
ventilation. Data are presented as median and 95% CI. Linear mixed models—vasopressors/inotropes as a ﬁxed factor: (a) pMMP-9 = 0.291,
(b) pTIMP-1 = 0.026, and (c) pMMP-9/TIMP-1 = 0.316; mechanical ventilation as a ﬁxed factor: (c) pMMP-9 = 0.715, (e) pTIMP-1 = 0.688, and
(f) pMMP-9/TIMP-1 = 0.871. MMP-9: matrix metalloproteinase-9; TIMP-1: tissue inhibitor of matrix metalloproteinase-1.
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to the number of samples which could be processed, samples
from the control groups were taken only once instead of ﬁve
times. Thirdly, due to a limited budget, CRP, PCT, and lac-
tate levels were not measured in all patients. Finally, aside
from age, gender, surgery, and comorbidities, we did not take
into account any other possible confounding factors such as
the use of corticosteroids, certain antibiotics, and amount
of ﬂuids received.
5. Conclusions
TIMP-1, unlike MMP-9 and MMP-9/TIMP-1 ratio, was a
good diagnostic and prognostic biomarker of sepsis after
major abdominal surgery. These biomarkers were also asso-
ciated with inﬂammation, sepsis-associated kidney and liver
injury, coagulopathy, and metabolic disorders. Future stud-
ies could possibly provide more insight into MMP-9 and
TIMP-1’s role in the pathophysiology of the sepsis-
associated organ dysfunction.
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